David Westenberg

David A. Westenberg, a partner in the Corporate Practice Group of WilmerHale in Boston, is author of the acclaimed book Initial Public Offerings: A Practical Guide to Going Public (Practising Law Institute, October 2009).

Recent posts

FAST Act Offers More Goodies to Emerging Growth Companies
Once again proving that you can’t judge a gift by its box, emerging growth companies (EGCs) received a pleasant, but oddly wrapped, surprise in December with the enactment of a new... Read more »
JOBS Act: Important Benefits for Startups Not on the IPO On-Ramp
The JOBS Act is probably best-known for creating an “IPO on ramp” intended to reduce the cost and complexity of going public, but the act also contains important benefits for startups... Read more »
The JOBS Act—The “IPO On-Ramp” Makes IPOs Easier
Enacted with great fanfare in early April, the JOBS Act is intended to improve access to the public capital markets for startup companies. The cornerstone of the act is the creation... Read more »
From Main Street to Wall Street—10 Things a Startup Should Do to Groom Itself for an Eventual IPO
You’ve got the vision, the core team, and even a little money. You’re prepared to devote enormous time and energy to your new startup. You’re unsure what the future will bring... Read more »
Ready, Set, Go Public—The 10 Things You Need to Do Now
The IPO market is open for business. The IPO market window has slammed shut. Which is it? Unless your IPO is pricing in the next week or two, it doesn’t matter.... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Video
The Bay Area and Beyond: Biocom Talks Innovation and COVID
A Fireside Chat with Biocom President & CEO Joe Panetta
Biocom

Sponsored · Whitepaper
What’s Next in Neuroscience Therapies
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders

From Our Editors · Special Report
Xcelerating Life Sciences San Francisco: Special Report
The AI, Big Data, and R&D Boom

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

Xconomy National

Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4

FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats

Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

David Westenberg

Recent posts

FAST Act Offers More Goodies to Emerging Growth Companies

JOBS Act: Important Benefits for Startups Not on the IPO On-Ramp

The JOBS Act—The “IPO On-Ramp” Makes IPOs Easier

From Main Street to Wall Street—10 Things a Startup Should Do to Groom Itself for an Eventual IPO

Ready, Set, Go Public—The 10 Things You Need to Do Now

Underwriters and Partners

The Bay Area and Beyond: Biocom Talks Innovation and COVID

What’s Next in Neuroscience Therapies

Xcelerating Life Sciences San Francisco: Special Report

Xconomy on Demand

We offer a number of ways to subscribe for free!